Matches in Wikidata for { <http://www.wikidata.org/entity/Q65360271> ?p ?o ?g. }
Showing items 1 to 46 of
46
with 100 items per page.
- Q65360271 description "clinical trial" @default.
- Q65360271 description "ensayu clínicu" @default.
- Q65360271 description "klinisch onderzoek" @default.
- Q65360271 description "клінічне випробування" @default.
- Q65360271 description "կլինիկական փորձարկում" @default.
- Q65360271 name "Biomarker Qualification for Risk of Mild Cognitive Impairment (MCI) Due to Alzheimer's Disease (AD) and Safety and Efficacy Evaluation of Pioglitazone in Delaying Its Onset" @default.
- Q65360271 name "Biomarker Qualification for Risk of Mild Cognitive Impairment" @default.
- Q65360271 type Item @default.
- Q65360271 label "Biomarker Qualification for Risk of Mild Cognitive Impairment (MCI) Due to Alzheimer's Disease (AD) and Safety and Efficacy Evaluation of Pioglitazone in Delaying Its Onset" @default.
- Q65360271 label "Biomarker Qualification for Risk of Mild Cognitive Impairment" @default.
- Q65360271 prefLabel "Biomarker Qualification for Risk of Mild Cognitive Impairment (MCI) Due to Alzheimer's Disease (AD) and Safety and Efficacy Evaluation of Pioglitazone in Delaying Its Onset" @default.
- Q65360271 prefLabel "Biomarker Qualification for Risk of Mild Cognitive Impairment" @default.
- Q65360271 P1050 Q65360271-AAF000DA-2FA6-4553-BF9C-0EEABA0F242F @default.
- Q65360271 P1132 Q65360271-6429909F-25C3-48C5-B314-CED90B8DE713 @default.
- Q65360271 P1476 Q65360271-B0DC725D-D8F2-40F9-984F-26AEAFEE0725 @default.
- Q65360271 P17 Q65360271-02560038-48DF-41E4-9993-A7A49609471F @default.
- Q65360271 P17 Q65360271-67A64161-669A-4A56-B2E3-CAA2A55E1B3B @default.
- Q65360271 P17 Q65360271-A51B2FC6-F8EB-4024-9B71-FA2220DE8031 @default.
- Q65360271 P17 Q65360271-B9403EA6-54C0-41A2-AC62-42341A317AC7 @default.
- Q65360271 P17 Q65360271-C3B856F5-BD61-46E0-BAD9-58C02E930978 @default.
- Q65360271 P1813 Q65360271-61EEC780-3F51-4339-8C32-990ADE37AA1C @default.
- Q65360271 P2899 Q65360271-CF14745F-C104-44E3-AE87-734A99CE63B8 @default.
- Q65360271 P3098 Q65360271-AAD031F0-EA8C-47DE-8635-B1C2D8E0CCC1 @default.
- Q65360271 P31 Q65360271-1B27AAB6-C7D5-4C9C-B99E-CB9C1635BDE8 @default.
- Q65360271 P4135 Q65360271-DBFB2ACC-FDFD-4272-A4F5-F2F960B2AF25 @default.
- Q65360271 P580 Q65360271-0660045C-7556-4E39-A3AC-0C7DFEF145EB @default.
- Q65360271 P582 Q65360271-56712858-878D-48DD-9B13-11884F28A015 @default.
- Q65360271 P6099 Q65360271-59601E59-01C6-453C-89D2-10A1B7E619A6 @default.
- Q65360271 P8363 Q65360271-8F10A476-4A8B-4367-9DF1-87284C42C224 @default.
- Q65360271 P1050 Q57859955 @default.
- Q65360271 P1132 "+3494" @default.
- Q65360271 P1476 "A Double Blind, Randomized, Placebo Controlled, Parallel Group Study to Simultaneously Qualify a Biomarker Algorithm for Prognosis of Risk of Developing Mild Cognitive Impairment Due to Alzheimer's Disease (MCI Due to AD) and to Test the Safety and Efficacy of Pioglitazone (AD-4833 SR 0.8 mg QD) to Delay the Onset of MCI Due to AD in Cognitively Normal Subjects" @default.
- Q65360271 P17 Q145 @default.
- Q65360271 P17 Q183 @default.
- Q65360271 P17 Q30 @default.
- Q65360271 P17 Q39 @default.
- Q65360271 P17 Q408 @default.
- Q65360271 P1813 "TOMMORROW" @default.
- Q65360271 P2899 "+65" @default.
- Q65360271 P3098 "NCT01931566" @default.
- Q65360271 P31 Q30612 @default.
- Q65360271 P4135 "+83" @default.
- Q65360271 P580 "2013-08-28T00:00:00Z" @default.
- Q65360271 P582 "2018-08-07T00:00:00Z" @default.
- Q65360271 P6099 Q42824827 @default.
- Q65360271 P8363 Q78089383 @default.